Coronavirus Stocks: Pfizer, BioNTech, Mesoblast
Australian biotech Mesoblast (MESO) rocketed 17% on earnings, and on a Covid-19 treatment partnership with Switzerland's Novartis (NVS). Volatile Mesoblast shares have a 60% year-to-date gain, but are down 44% from a late-August high.
This came out tonight on the US Investor business Daily.
Watch this space.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-362
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $4.508M | 3.130M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 17527 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 88487 | 10 |
View Market Depth
| Last trade - 13.43pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |